Company: STAA
Filing Date: 2025-08-29
Form Type: PREM14A
Source: 0001193125-25-192889
Chunk: 84

Company: STAAR SURGICAL CO
Filing Date: 2025-08-29
Form: PREM14A
Chunk 84
---
| • |     | the provisions of the Merger Agreement that restrict STAAR’s ability to solicit or participate in                                                                                                                                                    
 discussions or negotiations regarding alternative acquisition proposals with third parties, subject to specified exceptions, and that require STAAR to negotiate with Alcon (if Alcon so requests) prior to STAAR being able to terminate the Merger 
 Agreement to accept a Superior Proposal, and the possibility that STAAR’s obligation to pay the Company Termination Fee of $43,425,000 (or $14,475,000 in certain circumstances) to Alcon upon termination of the Merger Agreement could discourage  
 other potential acquirors from making alternative acquisition proposals to acquire STAAR;                                                                                                                                                            |

| • |     | the possibility that the price of STAAR’s common stock has not yet reflected all of the potential benefits                                                                                                                        
 and value to be derived from STAAR’s strategic initiatives, including reductions in operational expenses, new and expanded regulatory approvals for STAAR ICLs, and expansion of STAAR’s manufacturing operations in Switzerland; |

| • |     | the restrictions in the Merger Agreement on STAAR’s ability to conduct its business prior to the                                        
 consummation of the Merger, which could delay or prevent STAAR from pursuing business opportunities that may arise prior to the Merger; |

| • |     | the risks and costs of potential litigation in connection with the execution of the Merger Agreement and the                             
 consummation of the Merger and the other transactions contemplated therein, even if the claims asserted in such litigation are baseless; |

| • |     | the fact that the Merger Consideration will be taxable to STAAR stockholders for U.S. federal income tax 
 purposes;                                                                                                |

| • |     | the fact that some of STAAR’s directors and executive officers have interests in the Merger that are                                                                                                             
 different from, or in addition to, STAAR stockholders generally (as further described in the section of this proxy statement titled “—Interests of STAAR’s Executive Officers and Directors in the Merger”); and |

| • |     | the fact that STAAR’s remedies in the event that the Merger Agreement is terminated may be limited to the                                                                                                                                               
 Alcon Termination Fee of $72,375,000 in certain circumstances and certain other damages, associated enforcement costs and other indemnification and reimbursement obligations, which may be inadequate to compensate STAAR and its stockholders for any 
 damage caused, and that the Alcon Termination Fee may